Get Support

Learn Mode

AVTR - Avantor Inc

11

$7.90

$0.13 (1.673%)

At market close

$7.91

$0.01 (0.139%)

After Hours 4/2/26, 8:44 PM

2.78/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

AVTR

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$5.39B

Industry

Life Sciences Tools & Services

EPS (TTM)

-$0.78

P/E (TTM)

0.00

Div & Yield

--

FCF Payout Ratio

--

P/S (TTM)

0.82

P/B

0.97

Diluted Shares

678.20M

Ex-Dividend

--

Next Earnings

04-24

Forward P/E

9.52

Payout Ratio

--

P/FCF (TTM)

10.89

FCF Yield

9.19%

Earnings Yield

-9.84%

52 Week Range

Score Card

Explore Scores Tab

2.78

Average

Avantor Inc has seen its revenue decline by -3.41% over the past year, which means the company is losing sales/customers. Also, it has a seen its free cash flow decrease by -28.47% over the past year, which suggests its profits are declining.

Valuation Model

Key Score

4.00

Good

Management

4.00

Good

Growth

3.00

Average

Profitability

1.00

Very Bad

Fin. Health

5.00

Very Good

Dividends

--

--

Analyst

3.00

Average

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

1 new filing was in the last 7 days

Filter Form Types

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-04-01 08:06:37

Form ARS

Unknown Form Type

Filed on 2026-03-27 07:48:44

Form DEFA14A

Additional definitive proxy soliciting materials

Filed on 2026-03-27 07:43:46

Form DEF 14A

Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required

Filed on 2026-03-27 07:40:51

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-03-26 16:11:18

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-11 17:10:29

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-25 17:28:06

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-25 17:28:00

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-25 17:27:54

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-25 17:27:48

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-25 17:27:42

Form 8-K/A

(Amendment) Current report pursuant to Section 13 or 15(d)

Filed on 2026-02-25 16:36:36

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-03-25

High:

$19.95

152.5%

Avg:

$10.95

38.7%

Low:

$7.07

-10.5%

(% change is relative to the current stock price: $7.90)

Analyst Recommendations

Go to Analyst Tab

3.31

Average

12%

Strong Buy (3)

19%

Buy (5)

62%

Hold (16)

4%

Sell (1)

4%

Strong Sell (1)

About

Website
https://www.avantorsciences.com/
Address
Radnor Corporate Center, Building One, Suite 200, 100 Matsonford Road, Radnor PENNSYLVANIA, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1722482

Avantor, Inc. is a life science tools company that engages in providing mission-critical products and services to the life sciences and advanced technology industries. The company is headquartered in Radnor, Pennsylvania and currently employs 13,500 full-time employees. The company went IPO on 2019-05-17. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.

IPO Date

2019-05-17

Industry

Life Sciences Tools & Services

Total Employees

13,500

Exchange

New York Stock Exchange, Inc.

Reporting Currency

USD

GICS

Life Sciences Tools & Services

GICS Sub

Life Sciences Tools & Services

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences